Treatment of Chronic Hepatitis C Virus Infection: A Clinical and Virological Perspective

  • David R. Gretch
  • Stephen J. Polyak
  • Richard A. Willson
  • Robert L. CarithersJr.
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)


Hepatitis C virus (HCV), the etiologic agent of chronic non-A, non-B hepatitis,is a 9.4 kb positive strand RNA virus classified within the Flaviviridae family.1 The RNA genome of HCV encodes a single precursor polyprotein of 3011 amino acids, which is cleaved by host and viral proteases into a series of structural and non-structural proteins as reviewed elsewhere (Figure 1). (reviewed in reference 2) Although HCV gene products have not been definitively identified in infected hosts, they have been successfully expressed via genetic engineering.3,4 The HCV structural proteins (core and envelope) are thought to circulate in the blood of infected individuals as virion components, while the non-structural proteins (NS2-NS5) are thought to function as regulatory enzymes (e.g., protease, helicase, RNA replicase) during the intracellular phase of the viral life cycle.


Chronic Hepatitis Interferon Therapy Mixed Cryoglobulinemia Essential Mixed Cryoglobulinemia Alfa Interferon Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Choo, Q.-L., G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–362.PubMedCrossRefGoogle Scholar
  2. 2.
    van Doom, L.J. 1994. Molecular biology of the hepatitis C virus. J. Med. Virol 43: 345–356.Google Scholar
  3. 3.
    Hijikata, M., N. Kato, Y. Ootsuyama, et al. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. PNAS 88: 5547–5551.PubMedCrossRefGoogle Scholar
  4. 4.
    Grakoui, A., C. Wychowski, C. Lin, et al. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol 67: 1385–1395.PubMedGoogle Scholar
  5. 5.
    Houghton M, Weiner A, Han J, Kuo G, Choo QL. Molecular biology of the hepatitis C virus: Implications for diagnosis, development and control of disease. Hepatology 1991; 14 (2): 381–388.PubMedCrossRefGoogle Scholar
  6. 6.
    Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5’ noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A 1992; 89 (11): 4942–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Han JH, Shyamala V, Richman KH, et al. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5’ untranslated region and poly(A) tails at the 3’ end. Proc Natl Acad Sci USA 1991; 88 (5): 1711–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Weiner, A.J. M.J. Brauer, J. Rosenblatt, et al. 1991. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelpe and NS I proteins and the pestivinis envelope glycoproteins. Virol. 180: 842–848.Google Scholar
  9. 9.
    Weiner, A.J., H.M Geysen, C. Christopherson, et al. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. PNAS 89: 3468–3472.PubMedCrossRefGoogle Scholar
  10. 10.
    Chan, S.W., F. McOmish, E.C. Holmes, et al. 1992. Analysis of a new hepatitis C virus type and its phylogenetic realtionship to existing variants. J. Gen. Virol. 73: 1131–1141.Google Scholar
  11. 11.
    Simmonds P, Alberti A, Alter FU, et al. A proposed system for the nomenclature of hepatitis C viral genotypes [letter]. Hepatology 1994; 19: 1321–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Alter, M.J. 1993. The detection, transmission and outcome of hepatitis C virus infection. Infect. Agents Dis. 2: 155–166.Google Scholar
  13. 13.
    Knudsen F, Wantzin P, Rasmussen K, et al: Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease. Kidney International, 1993; 43: 1353–1356.PubMedCrossRefGoogle Scholar
  14. 14.
    Simon N, Courounce AM, LeMarrec N, et al. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney International 1994; 46: 504–511.PubMedCrossRefGoogle Scholar
  15. 15.
    Allender T, Medin C, Jacobson SH, et al. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virology 1994; 43: 415–419.CrossRefGoogle Scholar
  16. 16.
    Alter, M.J. 1991. Inapparent transmission of hepatitis C: footprints in the sand. Hepatol. 14: 389–391.CrossRefGoogle Scholar
  17. 17.
    Weiner, A.J. M.M Thaler, K. Crawford, et al. 1993. A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J. Virol. 67: 4365–4368.Google Scholar
  18. 18.
    Dienstag, I.L. 1986. Non-A, non-B hepatitis: evolving epidemiological and clinical perspective. Senrin. Liver Dis. 6: 67–81.Google Scholar
  19. 19.
    Alter HJ. Chronic consequences of non-A, non-B hepatitis. In: Current Perspectives in Hepatology, JH Lewis ed. 1989: 83–97.Google Scholar
  20. 20.
    Hopf U, Moller B, Kuther D, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10 (1): 69–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States_ N Engl J Med 1992; 327: 1899–1905.Google Scholar
  22. 22.
    Gretch, D., W. Lee, L. Corey. 1992. USe of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection is a diagnostic virology laboratory. J. Clin. Micro. 30: 2145–2149.Google Scholar
  23. 23.
    Kiyosawa, K., T. Sodeyama, E. Tanaka, et al. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatol. 12: 671–675.CrossRefGoogle Scholar
  24. 24.
    Van der Poel, C.L., Cuypers, H.T.M., Reesink, H.W., et al., 1991. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 337: 317–319.PubMedCrossRefGoogle Scholar
  25. 25.
    Rubin, R.A., M. Falestiny, P.F. Malet. 1994. Chronic hepatitis C. Advances in diagnostic testing and therapy. Arch. Intern. Med. 154: 387–392.Google Scholar
  26. 26.
    Wright TL. Hepatitis C virus infection and organ transplantation. In: Boyer JL, Ockner RK, eds. Progress in liver diseases. Vol. XI, Chapter 11, Philadelphia PA: WB Saunders Company. 1993: 215–230.Google Scholar
  27. 27.
    Alberti, A., L. Chemello, D. Cavalletto, et al. 1991. Antibody to hepatitis C virus and liver disease in healthy blood donors. Ann. Intern. Med. 114: 1010–1012.Google Scholar
  28. 28.
    Saito, I., T. Miyamura, A. Ohbayashi, et al. 1990. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. PNAS 87: 6547–6549.PubMedCrossRefGoogle Scholar
  29. 29.
    Nishioka, K., J. Watanabe, S. Furata, et al. 1991. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 67: 429–433.PubMedCrossRefGoogle Scholar
  30. 30.
    Bruix, J., J. Barrera, X. Calvet et al. 1989. Prevalence of antibodies to hepatitis C virus in Spanish patients with heptocellular carcinoma and hepatic cirrhosis. Lancet 2: 1004–1006.PubMedCrossRefGoogle Scholar
  31. 31.
    Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol, 1991; 9: 621–624.PubMedGoogle Scholar
  32. 32.
    Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Int Med 1992; 117: 574–577.Google Scholar
  33. 33.
    Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type It cryoglobulinemia N Engl J Med, 1992; 327: 1490–1495.Google Scholar
  34. 34.
    Johnson, R.J., Gretch, D.R., Yamabe, H. Membranoproliferative glomerulonephritis associated with hepatitis C infection. N. Engl. J. Med. 1993; 328: 465–470.PubMedCrossRefGoogle Scholar
  35. 35.
    Rollino C, Roccatello D, Giachino O, et al. Hepatitis C virus infection and membranous glomerulonephritis. Nephron 1991; 59: 319–320.PubMedCrossRefGoogle Scholar
  36. 36.
    Davada R, Peterson J, Weiner R, et al. Membranous glomerulonephritis in association with hepatitis C infection. Am J Kidney Dis 1993; 22: 452–455.Google Scholar
  37. 37.
    Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med, 1980; 69: 287–308.PubMedCrossRefGoogle Scholar
  38. 38.
    D’Amico GD, Colasanti G, Ferrario F, et al: Renal involvement in essential mixed cryoglobulinemia. Kidney International, 1989; 35: 1004–1014.PubMedCrossRefGoogle Scholar
  39. 39.
    Johnson JR, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney International 1994 (In press).Google Scholar
  40. 40.
    Bichard P, Ounanian A, Girard M, et al. High prevalence of hepatitis C virus RNA in the supernatant and the cryoprecipitate of patients with essential and secondary type II mixed cryoglobulinemia. J Hepatology 1994; 21: 58–63.CrossRefGoogle Scholar
  41. 41.
    Gretch, D.R., R.J. Johnson, H. Yamabe, et al. 1994. Clinical, immunological, and virological features of HCV-associated membranoproliferative glomerulonephritis. In: Viral hepatitis and liver disease; Springer Verlag, Tokyo, pp:218–221.Google Scholar
  42. 42.
    Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis [see comments]. N Engl J Med 1991; 325 (2): 98–104.PubMedCrossRefGoogle Scholar
  43. 43.
    Allain,J-P, Dailey SH, Laurian Y, et al. Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs. J Clin Invest 1991; 88: 1672–9.CrossRefGoogle Scholar
  44. 44.
    Gretch D, Corey L, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative compteitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis. 1994; 169: 1219–1225.PubMedCrossRefGoogle Scholar
  45. 45.
    Lau YN, Davis GL, Kniffen J, et al. Significance of hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–04.PubMedCrossRefGoogle Scholar
  46. 46.
    Gretch D, Han J, Willson R, et al. High titer hepatitis C virus infection is associated with advanced disease stage and resistance to inteferon therapy. Hepatology 1993; 18: 88A.Google Scholar
  47. 47.
    Kato N, Yokosuka K, Ito Y, Ohto M, Ornata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993; 18: 16–20.Google Scholar
  48. 48.
    Hagiwara, H., N. Hayashi, H. Fusamato, T. Kamada. 1993. Quantitiative analysis of hepatitis C virus RNA: relationship between the replicative level and the various stages of the carrier states or the response to interferon therapy. Gastroenterol. Jpn. 5: 48–51.Google Scholar
  49. 49.
    Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993, 104: 877–83.PubMedGoogle Scholar
  50. 50.
    Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 1992; 14 (1): 35–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Enamoto N, Takada A, Nakao T, Date T. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Comm 1990; 170: 1021–25.CrossRefGoogle Scholar
  52. 52.
    McOmish F, Chan SW, Dow BC, et al. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993; 33 (1): 7–13.PubMedCrossRefGoogle Scholar
  53. 53.
    Bukh J, Miller RH. Diagnostic and clinical implications of the different genotypes of hepatitis C virus. Hepatology 1994; 20: 256–259.PubMedGoogle Scholar
  54. 54.
    Sen, G.C., R.M. Ransohoff. 1993. Interferon-induced antiviral actions and their regulation. Adv. Virus Res. 42: 57–102.Google Scholar
  55. 55.
    Baron, S., F. Dianzani. 1994. The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res. 24: 97–110.PubMedCrossRefGoogle Scholar
  56. 56.
    Sen, G.C., P. Lengyel. 1992. The interferon system: a bird’s eye view of its biochemistry. J. Biol. Chem. 267: 5017–5020.Google Scholar
  57. 57.
    Vilcek, J., I.C. Oliveira. 1994. Recent progress in the elucisation of interferon-gamma actions: molecular biology and biological functions. Int. Arch. Allergy Immunol. 104: 311–316.Google Scholar
  58. 58.
    Muller, U., U. Steinhoff, L.F.L. Reis, et al. 1994. Functional role of type I and type II interferons in antiviral defense. Science 265: 1918–1921.CrossRefGoogle Scholar
  59. 59.
    Katze, M.G. 1993. Games viruses play: a strategic initiative against the interferon-induced dsRNA activated 68,000 Mr protein kinase. Semin. Virol. 4: 259–268.Google Scholar
  60. 60.
    Lengyel, P. 1982. Biochemistry of interferons and their actions. Ann. Rev. Biochem. 51: 251–282.Google Scholar
  61. 61.
    Hoofnagle, J.H., A. Di Bisceglie, M. Shindo. 1993. Antiviral therapy of hepatitis C- present and future. J. Hepatol. 17 (Suppl. 3): S130 - S136.PubMedCrossRefGoogle Scholar
  62. 62.
    Reichard O. Treatment of chronic hepatitis C. Scand J Infect Dis, 1994; Suppl 95: 1–56.CrossRefGoogle Scholar
  63. 63.
    Yun ZB, Reichard O, Chen M, et al: Serum Hepatitis C virus RNA levels in chronic Hepatitis C–Importance for outcome of interferon-alfa 2b treatment. Scand. J. Infect. Dis. 1994: 26: 263–270.PubMedCrossRefGoogle Scholar
  64. 64.
    Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon beta. Hepatology 1993; 18: 1319–1325.PubMedCrossRefGoogle Scholar
  65. 65.
    Shindo, M., A.M. Di-Bisceglie, L. Cheung et al. 1991. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann. Intern. Med. 115: 700–704.Google Scholar
  66. 66.
    Shindo, M., A.M. Di-Bisceglie, J.H. Hoofnagle. 1992. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatol. 15: 1013–1016.CrossRefGoogle Scholar
  67. 67.
    Saracco, G., M.L. Abate, M. Baldi, et al. 1994. Hepatitis C virus markers in patients with ton-term biochemical and histological remission of chronic hepatitis. Liver 14: 65–70.PubMedGoogle Scholar
  68. 68.
    Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497–502.PubMedGoogle Scholar
  69. 69.
    Pagliaro L, Craxi A, Cammaa C, et al. Interferon-a for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820–828.PubMedGoogle Scholar
  70. 70.
    Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau J-P, et al. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B hepatitis. Gastroenterology 1994; 106: 686–690.PubMedGoogle Scholar
  71. 71.
    Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108–2113.PubMedGoogle Scholar
  72. 72.
    Van Thiel DH, Gavaler JS, Wright HI, Friedlander L. Responses to a interferon (IFN) therapy are influenced by the iron content of the liver. Gastroenterology 1992; 102: 904A. (abstract)Google Scholar
  73. 73.
    Clemente MG, Congia M, Lai ME, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994; 125: 123–128.PubMedCrossRefGoogle Scholar
  74. 74.
    Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088–1094.PubMedCrossRefGoogle Scholar
  75. 75.
    Yoshioka, K., S. Kakumu, T. Wakita, et al. 1991. Detection of hepaitits C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus. Hepatol. 16: 293–299.CrossRefGoogle Scholar
  76. 76.
    Mita, E., N. Hayashi, H. Hagiwara, et al. 1994. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig. Dis. Sci. 39: 977–982.Google Scholar
  77. 77.
    Hino, K., S. Sainokami, K. Shimoda, et al. 1994. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis. J. Med. Virol. 42: 299–305.Google Scholar
  78. 78.
    Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med, 1987; 83: 726–730.PubMedCrossRefGoogle Scholar
  79. 79.
    Casato M, Lagana B, Antonelli G, et al. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood, 1991; 78: 3142–3147.PubMedGoogle Scholar
  80. 80.
    Knox TA, Hillyer CD, Kaplan MM, Berkman EM. Mixed cryoglobulinemia responsive to interferon-a. Am J Med, 1991; 91: 554–555.PubMedCrossRefGoogle Scholar
  81. 81.
    Taillan B, Ferrari E. Gamier G, et al. Low-dose interferon-a for mixed cryoglobulinemia associated with hepatitis C virus. Am J Med, 1992; 93: 476.Google Scholar
  82. 82.
    Ferri C, Marzo E, Longombardo G, et al. Interferon-a in a mixed cryoglobulinemia patients. A randomized, crossover-controlled trial. Blood, 1993; 81: 1132–1136.PubMedGoogle Scholar
  83. 83.
    Misiani R, Bellavita P, Domenico F, et al Interferon Alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med, 1994; 330: 751–756.PubMedCrossRefGoogle Scholar
  84. 84.
    Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha interferon therapy. Kidney International, 1994; (In Press).Google Scholar
  85. 85.
    DeVecchi A, Montagnino G, Pozzi C, et al. Intravenous methylprednisone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 1983; 19: 221–227.Google Scholar
  86. 86.
    Geltner D. Therapeutic approaches to mixed cryoglobulinemia. Springer Semin Immunopath 1988; 10: 103–113.CrossRefGoogle Scholar
  87. 87.
    Fong Ti, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196–199.Google Scholar
  88. 88.
    McHutchinson JG, Wilkes LB, Pockros P, et al. Pulse cortiocosteroid therapy increases viremia (HCV RNA) in patients with chronic hepatitis C infection. Hepatology 1993; 18: 87A.Google Scholar
  89. 89.
    Lindsay KL, Davis GL, Schiff ER, et al: Long-term response to higher doses of interferon alfa 2b treatment of patients with chronic Hepatitis C- a randomized controlled multicenter trial. Hepatology 1993; 18: 106A.Google Scholar
  90. 90.
    Marcellin P, Pouteau M, Boyer N, et al: Absence of efficacy of an increasing dosage schedule on the response rate during and after recombinant alfa interferon therapy in chronic Hepatitis C. Hepatology 1991; 14: 71A.Google Scholar
  91. 91.
    Feinuran SV, Williams B, Minuk G, et al: Treatment of chronic non-A, non-B Hepatitis blood related and sporadic with recombinant interferon alfa. Hepatology 1991; 14: 71A.Google Scholar
  92. 92.
    Jouet P, Roudot-Thoraval F, Dhumeaux D, et al: Comparative efficacy of Interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B. C Hepatitis. Gastroenterology 1994; 106: 686–690.PubMedGoogle Scholar
  93. 93.
    Saez-Royuela F, Pares JC, Moreno A, et al: High doses of recombinant alfa interferon or gamma interferon for chronic Hepatitis C: a randomized controlled trial. Hepatology 1991; 13: 327–331.PubMedCrossRefGoogle Scholar
  94. 94.
    Ascione, A., M. De Luca, C. Canestrini, et al. 1994. Three versus six MU interferon alfa-2b in the therapy of HCV-related chronic liver disease:randomised multicenter trial. Hepatology 20:155A; Abstract 234.Google Scholar
  95. 95.
    Tong MJ, Blatt LM, Resser K, et al: Treatment of patients with chronic HCV infection with a novel type I Interferon consensus interferon. Hepatology 1993; 18: 150A.Google Scholar
  96. 96.
    Omata M, Yokosuka O, Takano S, et al: Resolution of acute hepatitis C after therapy with natural Beta interferon. Lancet, 1991; 338: 914–915.PubMedCrossRefGoogle Scholar
  97. 97.
    Takano S, Samomura Y, Omata M, et al. Effects of interferon beta on non-A, non-B acute heaptitis: A prospective, randomized, controlled-dose study. Gastroenterology 1994; 107: 805–811.PubMedCrossRefGoogle Scholar
  98. 98.
    Kiyosawa K, Sodeyama T, Nakano Y, et al. Treatment of chronic non-A, non-B hepatitis with human interferon beta: a preliminary study,. Antiviral Res, 1989; 12: 151–161.PubMedCrossRefGoogle Scholar
  99. 99.
    Nakano Y, Kiyosawa K, Sodeyama T, Tanaka E. Comparative study of clinical, histological and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis.. Am J Gastroenterol, 1990; 85: 24–29.PubMedGoogle Scholar
  100. 100.
    Reichard O, Anderson J, Schvarcz R, et al. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058–1061.PubMedCrossRefGoogle Scholar
  101. 101.
    DiBisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649–654.CrossRefGoogle Scholar
  102. 102.
    Reichard O, Yun ZB, Sonneborg A, et al. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99–102.PubMedCrossRefGoogle Scholar
  103. 103.
    DiBisceglie AM, Fried MW, Swain MG, et al. Randomized double blind placebo-controlled trial of ribavirin therapy for chronic hepatitis C. Heaptology 1993; 18: 93A.Google Scholar
  104. 104.
    Mutchnick MG, Ehrinpreis MN, Kinzie JL, et al. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res. 1994; 24: 245–257.PubMedCrossRefGoogle Scholar
  105. 105.
    Mutchnick MG, Appelman HD, Chung HT, et al: Thymosin treatment of chronic hepatitis B. A placebo controlled pilot trial. Hepatology 1991; 14: 409–415.PubMedCrossRefGoogle Scholar
  106. 106.
    McHutchinson JG, Wilkes LB, Pockros PJ, et al: Pulse corticosteroid therapy increases viremia (HCV RNA) in patients with chronic Hepatitis C infection. Hepatology 1993; 18: 87A.Google Scholar
  107. 107.
    Fong TL, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196–199.PubMedGoogle Scholar
  108. 108.
    Magrin S, Craxi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alfa or corticosteroid treatment. Hepatology 1994; 19: 273–279.PubMedCrossRefGoogle Scholar
  109. 109.
    Perrillo R, Regenstein F, Peters M, et al: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis: A randomized, controlled trial. Ann. Intern. Med. 1988; 109: 95–100.PubMedCrossRefGoogle Scholar
  110. 110.
    Liaw YF, Sheen IS, Lin SM, et al: Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 1993; 13: 46–50.PubMedGoogle Scholar
  111. 111.
    Lai MY, Yang PM, Kao JH, et al: Combination therapy of alfa interferon and Ribavirin in patients with chronic Hepatitis C: an interim report. Hepatology 1993; 18: 93A.Google Scholar
  112. 112.
    Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812–817.PubMedCrossRefGoogle Scholar
  113. 113.
    Kakumu S, Yoshioka K, Wakita T, et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology, 1993; 105: 507–512.PubMedGoogle Scholar
  114. 114.
    Takikawa H, Yamanaka M, Miyake K, et al. Ursodeoxycholic acid therapy for chronic type C hepatitis: A multicenter dose finding trial. Curr Ther Res 1994; 55: 16–21.CrossRefGoogle Scholar
  115. 115.
    Takano S, Ito Y, Yokosuka O, et al. A multicenter randomized controlled dose study of ursodexycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558–564.PubMedCrossRefGoogle Scholar
  116. 116.
    Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986–988.PubMedGoogle Scholar
  117. 117.
    VanThiel DH, Friedlander L, Fagiuoli S, et al. Response to interferon alfa therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410–415.CrossRefGoogle Scholar
  118. 118.
    Olynyk J, Reddy R, DiBisceglie AM, et al. Hepatic iron concentration as a predictor of response to alpha interferon therapy in chronic hepatitis C. Hepatology 1993; 18: 90A.Google Scholar
  119. 119.
    Diodati G, Bonetti P, Novento F, et al. Treatment of chronic hepatitis C with recombinant human interferon alfa 2a: Results of a randomized controlled clinical trial. Hepatology 1994; 19: 1–5.PubMedCrossRefGoogle Scholar
  120. 120.
    Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after alpha-2b for 60 weeks. Hepatology 1994; 19: 280–285.PubMedCrossRefGoogle Scholar
  121. 121.
    Saracco G, Rosina F, Abate ML, et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alfa-2b. Hepatology 1993; 18: 1300–1305.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • David R. Gretch
  • Stephen J. Polyak
  • Richard A. Willson
  • Robert L. CarithersJr.

There are no affiliations available

Personalised recommendations